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Background—Mutations in SCN5A are identified in '20% to 30% of probands affected by Brugada syndrome (BrS).
However, in familial studies, the relationship between SCN5A mutations and BrS remains poorly understood. The aim
of this study was to investigate the association of SCN5A mutations and BrS in a group of large genotyped families.
Methods and Results—Families were included if at least 5 family members were carriers of the SCN5A mutation, which was
identified in the proband. Thirteen large families composed of 115 mutation carriers were studied. The signature type I ECG
was present in 54 mutation carriers (BrS-ECG1; 47%). In 5 families, we found 8 individuals affected by BrS but with a
negative genotype (mutation-negative BrS-ECG1). Among these 8 mutation-negative BrS-ECG1 individuals, 3, belonging
to 3 different families, had a spontaneous type I ECG, whereas 5 had a type I ECG only after the administration of sodium
channel blockers. One of these 8 individuals had also experienced syncope. Mutation carriers had, on average, longer PR and
QRS intervals than noncarriers, demonstrating that these mutations exerted functional effects.
Conclusions—Our results suggest that SCN5A mutations are not directly causal to the occurrence of a BrS-ECG1 and that
genetic background may play a powerful role in the pathophysiology of BrS. These findings add further complexity to
concepts regarding the causes of BrS, and are consistent with the emerging notion that the pathophysiology of BrS
includes various elements beyond mutant sodium channels. (Circ Cardiovasc Genet. 2009;2:552-557.)
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B rugada syndrome (BrS) is an inherited arrhythmia syn-drome with an increased risk of sudden death, resulting
from polymorphic ventricular tachycardia and/or ventricular
fibrillation in the absence of gross structural abnormalities.1
BrS is associated with ST-segment elevation in the right
precordial ECG leads, which have such a characteristic shape
(so-called type I ECG, here abbreviated as “BrS-ECG1,” see
Methods) that their presence is required for the diagnosis. A
BrS-ECG1 may occur spontaneously or be provoked by
sodium channel blocking drugs. Although BrS and a BrS-
ECG1 are intimately linked, not all patients with a BrS-
ECG1 are at risk of ventricular fibrillation, as individuals
with a BrS-ECG1 exhibit marked phenotypic variability,
ranging from sudden death victims to individuals in whom a
BrS-ECG1 is found by chance, but who remain asymptom-
atic.2 The phenotypic variability has spawned studies aimed
at finding modifying factors such as gender, age, and other
environmental factors.3,4 Recent experimental studies support
a role of the genetic background, although clinical observa-
tions indicate that the risk of sudden death of a BrS patient is
not increased if otherwise unexplained sudden death has
occurred in his/her family.5,6
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Mutations in the SCN5A gene, which encodes the pore-
forming subunit of the cardiac voltage-gated sodium channel,
are found in 20% to 30% of BrS patients.7,8 Five other genes
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(GPD1L, CACNA1C, CACNB2, SCN1B, and KCNE3) have
been associated with BrS, but the prevalence of variants in
these genes is yet unknown.9–12 SCN5A mutations may also
lead to progressive cardiac conduction defects, long-QT
syndrome type 3, or atrial standstill.13–15 Progressive cardiac
conduction defects and BrS are both associated with a loss of
function of the mutant sodium channel. Accordingly, “over-
lap” families who present a mixed phenotype with features of
both diseases exist.16–18 The causality of SCN5A mutations in
progressive cardiac conduction defects was proven by linkage
analysis.13,16,19 In contrast, SCN5A mutations in BrS were
discovered by a candidate gene approach20 and linkage data
are still lacking, with the exception of a large overlap family
in which the causal mutation is linked with a mixed pheno-
type.21 Of note, not only is the proportion of SCN5A mutation
carriers low, but also, conversely, BrS-ECGs1 were reported
among members of SCN5A-positive BrS families who did not
carry the familial SCN5A mutation.22,23 Clearly, the associa-
tion between BrS and SCN5A mutations is complex. In this
study, we set out to investigate this association in a larger
group of families.
Methods
This retrospective study was conducted at the center of reference for
rare arrhythmic diseases of Nantes University Hospital and at the
Academic Medical Center, University of Amsterdam, in accordance
with the local guidelines for genetic research and with the approval
of the local medical ethics committees. Informed written consent was
obtained from all patients.
Large genotyped BrS families in which 5 or more family members
carried a SCN5A mutation were included for the present investiga-
tion. An individual was defined as affected by BrS if he/she
displayed a BrS-ECG at baseline or after provocation with a class I
antiarrhythmic drug (BrS-ECG1).24 A BrS-ECG1 was defined as a
coved-type ST-segment elevation $0.2 mV at its peak followed
(without isoelectric separation) by a negative T wave in 2 or more
right precordial leads.25 Either intravenous ajmaline (1 mg/kg body
weight at a rate of 10 mg/min) or flecainide (2 mg/kg body weight
in 10 minutes with a maximum of 150 mg) were used for drug
testing. Drug challenge was not performed in patients younger than
16 years of age and in those showing severe conduction defects at
rest. Underlying structural heart disease was excluded by echocar-
diography, chest roentgenogram, and exercise testing. Laboratory
tests excluded acute ischemia and metabolic or electrolyte
disturbances.
ECG parameters that were analyzed, before and after drug testing,
were as follows: heart rate, PQ interval (in lead II), QRS duration,
maximal ST elevation (right precordial leads), and QTc duration in
V4 (Bazett’s formula).
Genetic Analysis
Genomic DNA was extracted from peripheral blood leukocytes using
standard protocols. All 28 exons of SCN5A were amplified by
polymerase chain reaction using intronic primers.26 Polymerase
chain reaction products were screened for a SCN5A mutation using
denaturing high performance liquid chromatography-DNA sequenc-
ing. DNA variants were disease-causing mutations, rather than
polymorphisms, if they were present in highly conserved regions of
SCN5A and absent in 200 control individuals. Annotation of muta-
tions was based on the cDNA reference sequence GenBank
NM_198056. Sequencing of the SCN5A gene was performed in
probands and in all mutation-negative BrS-ECG1 patients.
Statistical Analysis
ECG parameters were compared with Student t test. Clinical data are
expressed as mean value6SD for continuous data or proportions for
categorical data. A probability value ,0.05 was considered significant.
Results
Clinical and Electrocardiographic Results
Among a total of 444 genotyped probands with BrS-ECGs1
in whom molecular screening was conducted in our interna-
tional multicenter database, 118 (26%) carried an SCN5A
mutation. Thirteen of them, each with a different mutation
(Table 1), belonged to large families with $5 SCN5A-
positive members. For this analysis, all the screened members
of these 13 families were included, and they constituted the
study population (n5264; Table 2). A history of sudden
cardiac death at young age was present in 3 families. In the 13
probands, the workup that led to the diagnosis of BrS was
conducted because of (1) unexplained syncopal episode
Table 1. Summary of the Phenotype-Genotype Relationship in the Study Group (n513 Families)
Family
No.
Mutation
(Nucleotide)
Mutation
(Amino Acid)
Mutation
Carriers
Mutation
Positive
BrS-ECG1
Mutation
Positive
Not BrS ECG1
Mutation Positive,
Phenotype
Undetermined
Mutation
Negative
BrS ECG1
Type of
Mutation
A c.612–2A.G … 6 3 3 0 3 Wrong splice
B c.4222G.A p.Gly1408Arg 14 4 9 1 0 Missense27
C c.673C.T p.Arg225Trp 11 4 6 1 0 Missense28
D c.5164A.G p.Asn1722Asp 9 3 5 1 2 Missense
E c.396312T.C … 10 2 8 0 0 Wrong splice16
F c.4145G.T p.Ser1382Ile 9 3 5 1 1 Missense29
G c.2516T.C p.Leu839Pro 5 4 1 0 0 Missense
H c.2254G.A p.Gly752.Arg 6 4 2 0 0 Missense29,30
I c.1983–1993dup p.Ala665GlyfsX16 9 6 2 1 1 Frameshift, stop
J c.1603C.T p.Arg535X 9 5 4 0 0 Non sense29
K c.3667delG p.Ala1223ProfsX7 5 3 2 0 0 Frameshift, stop
L p.1570-Phe1571insIle 11 6 4 1 0 Insertion
M c.481G.A p.Glu161Lys 11 7 4 0 1 Missense23,29
Total 115 54 55 6 8
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(n54); (2) ECG performed because of chest pain (n52); (3)
ECG performed because of palpitations (n52); (4) ECG
performed for other reason (n54); and (5) ECG performed
because of a family history of sudden death (n51). Eleven of
13 probands had a spontaneous BrS-ECG1 (type I), whereas
1 showed a BrS-ECG1 only after drug provocation (family
D; Figure 1). The last proband (family L) suffered from
sudden cardiac death during car racing; his brother also died
during car racing from sudden cardiac death and that second
event initiated familial screening.
Genetic analysis of the probands’ relatives identified a total
of 115 carriers (Figure 1) of the familial SCN5A mutation and
149 mutation negative relatives (mutation negative unaf-
fected individuals not shown in Figure 1). In total, a sponta-
neous BrS-ECG1 was present in 21 of 115 mutation carriers
(18%) and in 3 of the noncarriers. Provocation testing,
performed in 67 mutation carriers and 63 noncarriers, was
positive in 33 additional mutation carriers and in 5 noncarri-
ers. Thus, among carriers of the familial mutation the pen-
etrance of the BrS phenotype increased from 18% at baseline
to 61% after drug testing (54/88 patients). Twenty-five
mutation carriers received an implantable cardioverter/
defibrillator.
At baseline, mutation carriers had, on average, significantly
longer PR (193637 ms versus 162629 ms, P,0.00001) and
QRS intervals (113620 versus 95614 ms, P,0.0001), com-
pared with the noncarriers (Table 2). There was a higher
proportion of patients affected by a first-degree AV block among
carriers (27/115, 23%) than among noncarriers (4/149, 3%,
Table 2. PR and QRS Duration in the 13 Families
(264 Members)
n PR Interval, ms QRS Interval, ms
Mutation positive BrS-ECG1 54 194637 113618
Mutation positive not BrS-ECG1 61 193637 113621
Mutation carriers (total) 115 193637* 113620**
Mutation negative BrS-ECG1 8 158625 94615
Mutation negative not BrS-ECG1 141 162631 94614
Mutation negative subjects (total) 149 162629* 95614**
Total 264
*P,0.00001; **P,0.001
Figure 1. Pedigrees of the 13 SCN5A-related BrS families. Squares represent males and circles represent females. Probands are indicated
by an arrow. Family members affected by the BrS phenotype (BrS-ECG1) before or after provocation challenge are represented with a left-
half ﬁlled symbol. Family members affected by progressive cardiac conduction disease are represented with a right half-ﬁlled symbol. Muta-
tion carriers without BrS phenotype (mutation negative BrS-ECG2) are in white. Patients with undetermined phenotype are shown with gray
symbol and unknown genotype is indicated by a “?”. Family members carriers of a SCN5A mutation are indicated with 1 and noncarriers
with 2. The noncarriers of the SCN5A mutation but affected by the BrS are circled (mutation negative BrS-ECG1). Patients who underwent
sodium channel blocker testing are indicated with a T. Unaffected mutation-negative individuals are not shown.
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P,0.001) and a higher proportion of patients affected by a
complete right bundle branch block among carriers (23/115,
20%) than among noncarriers (5/149, 3%, P,0.001).
Results in the Families With Individuals Who Had
a BrS-ECG1 but Did Not Carry the Familial
Mutation (Mutation Negative BrS-ECG1)
In 5 of the13 studied families, 8 individuals showed a BrS-
ECG1, but did not carry the familial mutation (mutation
negative BrS-ECG1 individuals; Figure 2). Among them, 3
(each from a different family) had a spontaneous BrS-ECG1,
whereas 5 had a BrS-ECG1 only after drug testing. One was
symptomatic (syncope; d2), whereas the other 7 were asymp-
tomatic (3 men and 4 women). Drugs or factors leading to
acquired Br-ECG1 have been excluded in these 8
individuals.24,31
These 5 families were composed of 44 mutation-positive
and 61 mutation-negative subjects in total (mutation-negative
BrS subjects not shown in Figure 1). Also in this subgroup,
mutation-positive individuals had, on average, significantly
longer PR intervals (180632 ms versus 158625 ms,
P50.001) and QRS durations (107618 ms versus 94615 ms,
P,0.0001) than mutation-negative individuals. Among the
noncarriers of these families, there were no significant dif-
ferences in conduction parameters between the subjects
showing a BrS ECG and the ones without ST segment
elevation (PR: 165618 ms versus 157626 ms, P50.3; QRS:
98614 ms versus 94615 ms, P50.4).
An electrophysiological study was performed in 5 BrS-
ECG nonmutation patients. The mean HV interval was 50 ms.
Ventricular tachyarrhythmias were inducible in 3 (1 with a
spontaneous BrS-ECG and 2 with a BrS-ECG induced by
ajmaline). Signal-averaged ECG was performed in all the
mutation negative BrS-ECG1 patients and was negative in
all. An implantable cardioverter/defibrillator was implanted
in these 3 patients. No arrhythmic event was registered during
a 52642 months follow-up period.
Genetic Analysis in the Mutation Negative
BrS-ECG1 Patients
To make sure that the BrS phenotype identified in these
patients was not related to another mutation of the SCN5A
gene, we have performed a complete sequencing of the
SCN5A gene. This sequencing failed to identify any mutation.
Discussion
We set out to investigate the association between the occur-
rence of a BrS-ECG1 and carriership of a SCN5A mutation.
For this purpose, we studied 13 families with BrS-ECGs1 in
whom at least 5 family members carried the familial SCN5A
mutation. We found that this association is complex, because
BrS-ECGs1 were only found in 18% of mutation carriers at
baseline and in 61% after drug testing, and conversely, 8
individuals had a BrS-ECG, but did not carry the familial
mutation.
These observations may suggest that carriership of a SCN5A
mutation is not causal to the occurrence of a BrS-ECG1.
Historically, the putative role of SCN5A mutations in BrS is
derived from the identification of loss-of-function mutations
in many BrS syndrome patients throughout the world.20 In
general, affected families are small, and genetic linkage data
are lacking, with exception of a large family with an overlap
syndrome where a sodium channel mutation cosegregated
with a complex phenotype.21 If gene-negative, phenotype-
positive patients (as present in 5 of these 13 families) would
have been found in the initial years of the genotyping efforts
in this disease entity, a causal role for SCN5A would have
been probably refuted. Biophysical (patch-clamp) studies of
the aberrant gene products (cardiac sodium channels) have
consistently demonstrated that their altered functional prop-
erties are compatible with the BrS phenotype.32 All BrS-
associated SCN5A mutants reported at present exhibit net
loss-of-function which is generally regarded as the inciting
pathophysiological mechanism of BrS (yet, whether reduced
sodium channel function acts by exacerbating spatial inho-
mogeneities in depolarization or in repolarization to cause the
signature ST elevations of BrS is still controversial).29
Among mutations found in our 13 families (Table 1), 2
mutations introduce wrong splice sites (c.612 to 2A.G and
c.396312T.C), 2 are frameshift mutations (c.3816delG and
c.1983 to 1993dup), 1 mutation introduces a premature stop
codon (p.Arg535X), and 1 mutation causes an in-frame
insertion (p.1570- Phe1571insIle). These mutations are all
likely to produce nonfunctional sodium channels as usually
identified in the BrS. The 7 remaining mutations are missense
mutations, 4 of which have been biophysically studied
(p.Glu161Lys,23,30 p.Gly752Arg,27,30 p.Gly1408Arg,28 and
p.Arg225Trp33) and have shown to produce a strong decrease
in peak sodium current. Although no functional data are
available for the remaining 3 missense mutations
(p.Ser1382Ile, p.Leu839Pro, and p.Asn1722Asp), we found
that mutation carriers have, on average, longer PR intervals
and QRS durations than noncarriers. These findings are
consistent with previous reports17,30 and suggest that the
mutant channels produce less sodium current, as sodium
current reduction causes cardiac conduction slowing. Thus,
Figure 2. Electrocardiographic patterns in
the mutation negative members affected by
the BrS phenotype (mutation negative BrS-
ECG1). Only leads V1 and V2 are reported
for each patient. Patients a1, a2, and m1 had
a spontaneous BrS phenotype, and the ECG
presented here has been recorded before
sodium channel blocker challenge, whereas a
type 1 BrS-ECG was revealed after sodium
channel blocker administration in patients a3,
d1, d2, f1, and i1 (ECGs were recorded at
maximum dose of sodium channel blocker).
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the apparent lack of association between carriership of a
SCN5A variant and a BrS-ECG1, as observed in our study
population, cannot be explained by the fact that these SCN5A
variants are no disease-causing mutations. There is also no
reason to believe that the subjects with BrS-ECG1, who do
not carry the familial SCN5A mutation, have no true BrS.
Indeed, among the genotype-negative phenotype-positive pa-
tients, 3 in 3 different families had a spontaneous BrS-
ECG1, whereas 5 had a BrS-ECG1 only after sodium
channel blockers. We have found no other clinical abnormal-
ities to explain the electrocardiographic aspect of BrS. One of
these individuals was symptomatic with syncope before the
study. Finally, the electrophysiological study induced ventric-
ular fibrillation in 3 of these 5 patients, as previously reported
in BrS.8,34,35
A novel notion to emerge from our observation that some
patients have a BrS-ECG1, but do not carry the familial
SCN5A mutation, is that modulating factors within the studied
families (genetic background) are sufficiently powerful to
evoke a BrS-ECG1. These observations are in line with
emerging experimental studies, which indicate that disparate
genetic backgrounds confer disparate susceptibilities to the
effects of a single loss-of-function mutant sodium channel.6
Clearly, the relevant elements in the genetic background may
encompass all proteins and molecules that play a role in the
pathophysiology of BrS. For instance, such genes may
include not only those that encode ion channel subunits but
also those that encode molecules that modify cardiac struc-
ture (eg, fibrosis), thereby facilitating arrhythmias. Hence, it
seems conceivable that the genetic background in some
families is so strongly conducive to the occurrence of a
BrS-ECG1 that a BrS-ECG1 occurs even in the absence of
a SCN5A mutation or drug provocation (spontaneous BrS-
ECG1). This might point to the fact that a loss-of-function
SCN5A mutation, on its own, might not be sufficient to cause
BrS but could act like a revelatory factor as sodium channel
blocker challenge.
Limitations
All the genes known to be involved in the occurrence of the
BrS have not been sequenced. Then it is possible that other
gene mutations are responsible for the Brugada within the
families presented in the study. A provocation testing has not
been performed in all the family members, and then it is
possible that we have underestimated the frequency of the
BrS within these families.
Conclusion
We provide novel clinical evidence to suggest that genetic
background may play a powerful role in the pathophysiology
of BrS. These findings add further complexity to concepts
regarding the causes of BrS and are consistent with the
emerging notion that the pathophysiology of BrS includes
various elements beyond mutant sodium channels that pro-
duce reduced sodium current.
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CLINICAL PERSPECTIVE
This study focused on the complexity of the genetic background in Brugada syndrome (BrS). Mutations in SCN5A are
present in '20% to 30% of probands affected by BrS. However, in familial studies, the relationship between SCN5A
mutations and BrS remains to be demonstrated. In this investigation, Probst et al investigated the relationship between the
presence of SCN5A mutations and BrS ECG in 13 families in which the proband and at least 4 other family members were
carriers of a SCN5A mutation. The authors demonstrated that the penetrance of the BrS is low. We also confirmed that
mutation carriers had, on average, longer PR and QRS intervals than noncarriers, demonstrating that these mutations
exerted functional effects. The major finding of this investigation is that in 5 of these 13 families, 8 family members
affected by BrS were not carriers of the SCN5A mutation. These observations suggest that SCN5A mutations probably act
as a major modulating factor revealing the syndrome, but it is likely that other factors like the genetic background play an
important role in the occurrence of the disease. Overall, these results indicate that BrS is not a monogenic mendelian
disease but probably an oligogenic disease. The low penetrance of the disease and the presence of so-called phenocopies
demonstrated that there may not be a direct link between the presence of the SCN5A mutations and BrS. These results have
to be taken in account for the genetic counseling of the patients.
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